GPB cream reduces excessive underarm sweating

Abstract

British Journal of DermatologyVolume 185, Issue 2 p. e40-e40 Plain Language SummaryFree Access GPB cream reduces excessive underarm sweating First published: 16 August 2021 https://doi.org/10.1111/bjd.20532AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Abstract Linked Article: Abels et al. Br J Dermatol 2021; 185:315–322. Approximately 5% of people worldwide suffer from permanent excessive sweating, so-called ‘primary hyperhidrosis’, which has a severe impact on their quality of life. Yet, more than 50% of all people with hyperhidrosis receive no treatment. Patients with primary axillary hyperhidrosis suffer from an excessive amount of sweat production in the armpits beyond what is needed in order to regulate normal body temperature. In this clinical trial, conducted in Germany, Hungary, Sweden, Denmark and the UK, 171 patients with this condition applied either cream containing 1% of glycopyrronium bromide (GPB) or cream without GPB (a placebo, which looked like the cream being tested but that did not contain any medicine) every day for 4 weeks. Reduction in total sweat production (measured by weighing sweat absorbed in armpits over a 5-minute period) was statistically significantly higher for the 1% GPB cream compared with the placebo cream. Use of cream improved patient’s quality of life. Only mild or moderate side-effects were reported by patients; the most reported one was a dry mouth. The cream did not irritate the skin in their armpits. This study provides further evidence that this cream is effective for treatment of primary axillary hyperhidrosis and that a cream formulation is beneficial in terms of local tolerability and overall safety. The long-term safety and effectiveness part of the clinical trial for this treatment (over a period of 72 weeks) is currently underway. These data will be another step towards approval for this treatment in various European Union countries. In conclusion, GPB cream may provide an effective new treatment option for patients with excessive underarm sweating. Volume185, Issue2August 2021Pages e40-e40 RelatedInformation